food thought
jan feb iqvia sale particularli azn
outlook highlight track new drug launch
anticip difficult due number drug launch
specialti area prescript weekli track product
unreli drug prescrib via pharmaci therefor
publish iqvia sale represent product suppli
channel us januari februari releas yesterday
azn product ramp encourag particularli highlight posit
imfinzi ramp
significantli improv sinc present pacif data stage
unresect lung cancer late iqiva sale track ahead
consensu cse vs consensu fasenra initi
launch ramp start faster competitor nucala
imfinzi fasenra
azn product
product explor includ ocrevu bolu benefit hemlibra
launch line cse shingrix signific switch zostavax
well remicad biosimilar cimzia
reiter azn outperform take opportun reiter
outperform rate azn view azn growth prospect
attract compar peer particular sale ramp imfinzi
fasenra posit signal demonstr report well
tagrisso lynparza farxiga coupl strong growth em
clearli start drive inflect sale genericis matur
product eas target price
week launch
iqiva feb credit suiss estim consensu azn compani consensu
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
trend azn product posit
imfinzi set beat consensu expect figur show develop
market sinc launch imfinzi sinc pacif data stage
unresect lung cancer includ guidelin launch taken
iqvia sale tend strong correl report sale
oncolog drug therefor figur present impli ramp base
cs forecast consensu believ clearli
demonstr abil imfinzi exceed current consensu expect
fasenra track well vs nucala fasenra market three
month us xolair current domin biolog asthma space nucala
distant second moder growth figur compar launch
fasenra nucala faster ramp give us confid room three
increas biolog penetr sever asthma figur
iqiva feb credit suiss estim consensu azn compani consensu march
food thought
week launch
gsk shingrix switch market figur show iqvia sale zostavax
merck old vaccin shingl shingrix gsk new vaccin approv
market appear switch quickli shingrix last three
month compar histor report sale zostavax iqvia sale suggest
strong overlap trend correl therefor impli iqvia sale progress
necessari reach cs consensu forecast figur
believ opportun shingrix exceed expect
compani data credit suiss research consensu evalu pharma
roch ocrevu hemlibra
ocrevu uptick jan feb roch continu highlight bolu ppm
patient boost initi launch ocrevu mid bolu kept growth
rate month month low novemb howev benefit
bolu patient return second infus also boost sale
food thought
though roch highlight letter everyon elig
next cycl immedi start treatment end previou cycl iqvia
sale suggest pickup growth last three month iqvia sale
report sale well align
hemlibra initi ramp line cs expect initi ramp
hemlibra gradual line small size inhibitor popul
haemophilia potenti conserv patient assum hemlibra sale
well captur iqvia sale estim ramp broadli line
forecast note death arisen patient treat
hemlibra await inform mani conclus compani
confirm death link hemlibra
dupix trend continu line ramp
remicad biosimilar make littl impact brand remicad iqvia gross
sale appear fairli stabl figur howev estim increas
rebat remicad suggest increas price pressur
cimzia iqvia sale also fairli stabl estim rebat decreas
food thought
figur remicad biosimilar cimzia iqvia
food thought
charl martineau pm univers toronto compani mention price
